Scott Henry

“You mentioned the lipidated and non-lipidated peptide approaches. Could you talk a little bit about the advantages and the differences between those two approaches, and eventually would you narrow it down to one, or would you keep both going all the way.”

“It sounds like there's a lot of progress going on behind the scenes as far as building momentum for future sales. Could you give us a sense of how we should think about the timing of when that traction should start?”

“And good morning or afternoon, depending on your location. A couple questions. First, on the last conference call, you mentioned the CPT1 code, reimbursement code was to be filed in mid-June.”

“Starting with a couple of questions on the metrics. First, when you talk about the 255 orders, is that the same as what historically was referred to as authorizations?”

“Not looking for specifics, but just curious your thoughts, obviously, given that it's June 25th.”